The basis of current and future therapy for inflammatory bowel disease

American Journal of Medicine

Volumn 100, Issue 6, 1996, Pages 656-662

  Elson, Charles O ^a  

^a University of Alabama at Birmingham School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOTRIENE; MESALAZINE; OLSALAZINE; PROSTAGLANDIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL FEATURE; COLON BIOPSY; CROHN DISEASE; DISEASE ASSOCIATION; EDEMA; ENTERITIS; ERYTHEMA; HUMAN; IMMUNE SYSTEM; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REVIEW; ULCERATIVE COLITIS;

EID: 0030175929     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00049-6     Document Type: Article

References (26)

1. 1. Kirsner JB, Shorter RG. Inflammatory Bowel Disease. 4th ed. Baltimore: Williams & Wilkins; 1995.
2. 2. Bayless TM, ed. Current Management of Inflammatory Bowel Disease. Toronto: BC Decker, 1989.
3. 3. Peppercorn MA. Advances in drug therapy for inflammatory bowel disease. Ann Intern Med. 1990;112:50-60.
4. 4. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-895.
5. 5. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995;40:296-304.
6. 6. Courtney MG, Nunes DP, Bergin CF, et al. Randomized comparison of olsalazine and mesalamine in prevention of relapses in ulcerative colitis. Lancet. 1992;339:1279-1281.
7. 7. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991;115:350-355.
8. 8. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894-1898.
9. 9. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77:847-869.
10. 10. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86:249-266.
11. 11. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. NEJM. 1994;331:836-841.
12. 12. van Dulleman HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
13. 13. Elliott MJ, Maini RN, Feldmann M, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-1110.
14. 14. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol. 1995;154:5492-5499.
15. 15. MacDermott RP, Elson CO, eds. Mucosal Immunology I. Philadelphia: WB Saunders; 1991.
16. 16. Elson CO, McCabe RPJ. The immunology of inflammatory bowel disease. In: Kirsner JB, Shorter RG, eds. Inflammatory Bowel Disease. 4th ed. Baltimore: Williams & Wilkins; 1995:203-251.
17. 17. O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology. 1991; 101:39-46.
18. 18. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249-1252.
19. 19. Present DH. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am. 1989;18:57-71.
20. 20. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. NEJM. 1995;332:292-297.
21. 21. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. NEJM. 1994;330:1841-1845.
22. 22. Dieleman LA, Beagley KW, Elson CO. Effect of immunosuppressive agents on monocyte generation and cytokine expression. Inflam Bowel Dis. 1995;1:266-275.
23. 23. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344-1367.
24. 24. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity. 1995;3:171-174.
25. 25. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 1992;257:792-795.
26. 26. Strom TB, Kelley VR, Murphy JR, et al. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules. Annu Rev Med. 1993;44:343-353.